inhibition of rip1 to prevent acute gvhd
Published 1 year ago • 90 plays • Length 3:25Download video MP4
Download video MP3
Similar videos
-
1:52
results of phase i study of mcl-1 inhibition with azd5991 in r/r hematologic malignancies
-
1:21
overview of the role of non-covalent btk inhibitors in the era of covalent btk inhibitors
-
1:54
a novel clinical trial endpoint for acute gvhd
-
3:55
itacitinib in patients with acute gvhd
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
2:32
the growing role of anti-pd1 inhibitors in the frontline treatment of hl
-
5:12
phase ib/ii study of ptcy, abatacept & short-course tacrolimus for gvhd prevention following pbsct
-
2:00
the development of anti-fibrotic agents for treating myelofibrosis
-
12:49
3mensio ct pre-case planning: valve-in-valve tavr in homograft
-
16:13
3mensio ct pre-case planning: valve-in-valve tavr in trifecta
-
19:50
3mensio ct pre-case planning: redo-tavr with prior evolut pro
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
1:05
unmet needs in gvhd & the promise of regenerative medicine
-
6:11
first-in-human study of the menin-kmt2a inhibitor jnj-75276617 in r/r acute leukemias
-
4:17
novel-based approaches and the future of acute gvhd
-
2:42
mrd to identify those who benefit the most from flt3 inhibition with gilteritinib in cr1 of aml
-
2:03
prognostic significance of molecular mrd in npm1-mutated aml treated with venetoclax-based therapy
-
3:01
the role of piez01 variants in patients with mds
-
0:50
update on the pimms trial of ivosidenib for patients with idh1-mutated ccus
-
1:31
risk-adjusted safety analysis of pacritinib for patients with mf
-
3:55
ziftomenib: a menin inhibitor for r/r npm1-mutated aml
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo